Patterns of melastatin mRNA expression in melanocytic tumors
Patterns of melastatin mRNA expression in melanocytic tumors
复制标题
DOI：
10.1053/hupa.2000.19441
复制
发表时间：
2000-11-01
期刊：
影响因子：
3.3
通讯作者：
Duncan, LM
中科院分区：
文献类型：
--
作者：
Deeds, J;Cronin, F;Duncan, LM
黑素细胞特异性基因 Melastatin (MLSN1) 在人和小鼠细胞系的体外显示 mRNA 表达与转移潜力呈负相关。原发性皮肤黑色素瘤中的 Melastatin mRNA 表达也被发现与无病生存相关。以前从未描述过痣、原发性黑色素瘤和黑色素瘤转移瘤中 Melastatin mRNA 表达的组织学模式。使用 S-35 标记探针进行原位杂交，我们检测了 64 例正常皮肤、良性黑素细胞痣、原发性皮肤黑色素瘤和黑色素瘤转移瘤中 Melastatin mRNA 的表达。在所有良性黑素细胞增殖中均观察到 Melastatin mRNA 无处不在的黑素细胞表达（14 例中的 14 例），尽管一些痣显示随着真皮深度的增加，Melastatin 表达呈梯度下降（14 例中的 3 例）。在 49% 的原发性皮肤黑色素瘤中观察到 Melastatin mRNA 的均匀表达（37 例中的 18 例，包括 1 例原位黑色素瘤）。在 53% 的侵袭性黑色素瘤样本（36 个中的 19 个）和 100% 的黑色素瘤转移样本（11 个中的 11 个）中发现了部分黑色素瘤的 Melastatin mRNA 丢失。没有 mRNA 丢失的原发性黑色素瘤的厚度范围为 0.17 至 2.75 毫米（中位数为 0.5 毫米；平均值为 0.73 毫米），而显示 Melastatin mRNA 下调的肿瘤厚度范围为 0.28 至 5.75 毫米（中位数为 1.7 毫米；平均值为 2.13 毫米）。没有可检测信号的黑色素瘤细胞的局灶性聚集或结节是最常见的褪黑素丧失模式（19 例中的 13 例），而在 19 例中仅观察到 1 例真皮黑色素瘤细胞的褪黑素 mRNA 表达完全丧失。两种侵袭性黑色素瘤表现出分散的、非局灶性的 Melastatin mRNA 丢失模式。在检查的 11 个黑色素瘤转移中，64% 显示局灶性 Melastatin mRNA 丢失，36% 完全丢失 Melastatin mRNA 表达。我们观察到原发性黑色素瘤中 Melastatin mRNA 表达的几种模式，这些模式可能与良性黑素细胞痣中的表达有所区别。褪黑素 mRNA 表达似乎与黑色素细胞肿瘤进展、黑色素瘤肿瘤厚度和黑色素瘤转移的可能性相关。 HUM PATHOL 31:1346-1356，版权所有 (C) 2000，W.B.桑德斯公司。
The melanocyte-specific gene Melastatin (MLSN1) shows an inverse correlation of mRNA expression with metastatic potential in human and murine cell lines in vitro. Melastatin mRNA expression in primary cutaneous melanoma also has been found to correlate with disease-free survival. The histologic patterns of Melastatin mRNA expression in nevi, primary melanoma, and melanoma metastases have not been described previously. Using in situ hybridization with S-35-labeled probes, we examined Melastatin mRNA expression in 64 cases of normal skin, benign melanocytic nevi, primary cutaneous melanomas, and melanoma metastases. Ubiquitous melanocytic expression of Melastatin mRNA was observed in all benign melanocytic proliferations (14 of 14), although some nevi showed a gradient of reduced Melastatin expression with increased dermal depth (3 of 14). Uniform expression of Melastatin mRNA was observed in 49% of primary cutaneous melanomas (18 of 37 cases, including 1 case of in situ melanoma). Melastatin mRNA loss by a portion of the melanoma was identified in 53% of the invasive melanoma samples (19 of 36) and 100% of the melanoma metastases (11 of 11). Primary melanomas without mRNA loss ranged in thickness from 0.17 to 2.75 mm (median, 0.5 mm; mean, 0.73 mm), whereas tumors that showed Melastatin mRNA down-regulation ranged in thickness from 0.28 to 5.75 mm (median, 1.7 mm; mean, 2.13 mm). A focal aggregate or nodule of melanoma cells without detectable signal was the most commonly observed pattern of Melastatin loss (13 of 19 cases), whereas complete loss of Melastatin mRNA expression by ah of the dermal melanoma cells was observed in only 1 of the 19 cases. Two invasive melanomas displayed a scattered, nonfocal pattern of Melastatin mRNA loss. OF the 11 melanoma metastases examined, 64% displayed focal Melastatin mRNA loss, and 36% had complete loss of Melastatin mRNA expression. We observed several patterns of Melastatin mRNA expression in primary melanoma that may be distinguished from expression in benign melanocytic nevi. Melastatin mRNA expression appears to correlate with melanocytic tumor progression, melanoma tumor thickness, and the potential for melanoma metastasis. HUM PATHOL 31:1346-1356, Copyright (C) 2000 by W.B. Saunders Company.